XELIRI Noninferior to FOLFIRI as Second-Line Therapy for Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Modified XELIRI (Capecitabine Plus Irinotecan) Versus FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan), Both Either With or Without Bevacizumab, as Second-Line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-Label, Randomised, Non-Inferiority, Phase 3 Trial
Lancet Oncol 2018 Mar 16;[EPub Ahead of Print], RH Xu, K Muro, S Morita, S Iwasa, SW Han, W Wang, M Kotaka, M Nakamura, JB Ahn, YH Deng, T Kato, SH Cho, Y Ba, H Matsuoka, KW Lee, T Zhang, Y Yamada, J Sakamoto, YS Park, TW KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.